Emergent Biosolutions INC Form 4 insider transactions

Director Donald W. DeGolyer reports the acquisition of common stock and stock options in Emergent BioSolutions Inc. on April 30, 2025.

Director Louis W. Sullivan reports acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, disposed of 561 shares of common stock on April 7, 2025, to cover tax obligations related to vesting and settlement of restricted stock units.

Coleen Glessner, EVP at Emergent BioSolutions, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, files an amended Form 4 to correct a clerical error in the previously reported amount of securities beneficially owned following a transaction involving restricted stock units.

Director Neal Franklin Fowler of Emergent BioSolutions Inc. sold 35,000 shares of common stock on March 12, 2025, at a weighted average price of $5.83.

Director Kathryn C. Zoon of Emergent BioSolutions Inc. (EBS) sold 10,000 shares of common stock at a price of $5.73 per share on March 12, 2025.

Emergent BioSolutions CEO Joseph Papa reports the acquisition of 250,000 employee stock options, vesting upon achievement of specific stock price performance hurdles.

Jessica Perl, SVP, General Counsel, and Corporate Secretary of Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options, as well as the disposal of common stock.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions, reports acquisition of shares and stock options.

EVP and CFO Richard Lindahl reports acquisition of restricted stock units and employee stock options in Emergent BioSolutions.

Simon Lowry, SVP, R&D, CMO of Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, reports acquiring 62,500 shares of common stock and 62,500 employee stock options.

Emergent BioSolutions CEO Joseph Papa acquired 282,500 performance stock units and stock options on March 6, 2025, according to a recent SEC filing.

Coleen Glessner, EVP at Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, disposed of 292 shares of common stock on March 5, 2025, to cover tax obligations related to vesting and settlement of restricted stock units.

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions Inc., reports adjustments in beneficial ownership due to performance stock unit vesting and tax withholdings.

Coleen Glessner, EVP at Emergent BioSolutions, reports adjustments in her beneficial ownership due to performance stock unit payouts and tax withholdings.

Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions, reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Jessica Perl, SVP, General Counsel, and Corporate Secretary of Emergent BioSolutions, reports disposing of 918 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Form 4 filing reveals that Simon C. Lowry, SVP, R&D, CMO of Emergent BioSolutions, acquired shares and stock options on December 15, 2024.

Coleen Glessner, an executive at Emergent BioSolutions, sold 18,674 shares of common stock to cover tax obligations.

Donald W. DeGolyer, a director at Emergent BioSolutions Inc., sold 25,000 shares of the company's common stock on November 12, 2024.

Marvin L. White, a director at Emergent BioSolutions Inc., sold 14,287 shares of common stock on November 11, 2024.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, sold 632 shares of common stock to cover tax obligations.

EVP and CFO of Emergent BioSolutions, Richard S. Lindahl, reports acquiring 15,000 shares of common stock through restricted stock units.

William Hartzel, SVP of Bioservices at Emergent BioSolutions, reports acquiring 15,000 shares of common stock through restricted stock units.

EVP Jennifer Lynne Fox reports acquisition of 15,000 shares of Emergent BioSolutions Inc. through restricted stock units.

Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions, reports the disposal of 85 shares of common stock to cover tax obligations.

Jennifer Lynne Fox, EVP, Ext Aff, GC, Corp Sec of Emergent BioSolutions Inc., reports disposition of shares to cover tax obligations.